Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ELANE | P08246 | 1/20 | 0.39 |
| ▸ | MAOB | P27338 | 2/20 | 0.37 |
| ▸ | NR1H2 | P55055 | 3/20 | 0.36 |
| ▸ | NR1H3 | Q13133 | 3/20 | 0.36 |
| ▸ | MAPT | P10636 | 3/20 | 0.36 |
| ▸ | TAS2R14 | Q9NYV8 | 1/20 | 0.36 |
| ▸ | RAB9A | P51151 | 1/20 | 0.36 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.35 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.35 |
| ▸ | LMNA | P02545 | 1/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | GRM6 | O15303 | 1/20 | 0.34 |
| ▸ | RXRA | P19793 | 1/20 | 0.34 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.34 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.34 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.34 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.32 |
| ▸ | ATM | Q13315 | 1/20 | 0.32 |
| ▸ | HPGD | P15428 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11907366 | 0.86 | ALPL (0.39) | ELANEMAPTRAB9ANPSR1L3MBTL1 | |
| SCHEMBL13397730 | 0.85 | ELANE (0.40) | ELANEMAPTRAB9ANPSR1L3MBTL1 | |
| SCHEMBL1534096 | 0.84 | ELANE (0.41) | ELANEMAPTRAB9ANPSR1L3MBTL1 | |
| SCHEMBL1534095 | 0.84 | MAOB (0.41) | MAOBMAPTTAS2R14RAB9ANPSR1 | |
| SCHEMBL20370133 | 0.83 | GRM6 (0.41) | ELANEMAPTRAB9ANPSR1L3MBTL1 | |
| SCHEMBL1687962 | 0.81 | ELANE (0.39) | ELANEMAPTRAB9ANPSR1L3MBTL1 | |
| SCHEMBL11908652 | 0.80 | ELANE (0.38) | ELANEMAOBMAPTRAB9ANPSR1 | |
| SCHEMBL19634982 | 0.79 | MAOB (0.43) | MAOBMAPTTAS2R14RAB9ANPSR1 | |
| SCHEMBL1534042 | 0.79 | RXRA (0.46) | MAPTL3MBTL1TDP1RXRACYP2C9 | |
| SCHEMBL1534079 | 0.78 | HSD17B10 (0.44) | MAOBMAPTTAS2R14RAB9ANPSR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3275861-A1 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2018-01-31 | — | — | EP | disclosed |
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. | 2017-11-23 | — | — | US | disclosed |
| EP-2470500-B1 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS INC (US) | 2017-10-04 | — | — | EP | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-9624166-B2 | Tetracycline compounds | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2017-04-18 | — | — | US | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| US-20120208788-A1 | Tetracycline Compounds | TETRAPHASE PHARMACEUTICALS, INC. | 2012-08-16 | — | — | US | disclosed |
| EP-2470500-A2 | TETRACYCLINE COMPOUNDS | Tetraphase Pharmaceuticals, Inc. (US) | 2012-07-04 | — | — | EP | disclosed |
| WO-2011025982-A2 | TETRACYCLINE COMPOUNDS | TETRAPHASE PHARMACEUTICALS, INC. (US) | 2011-03-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170334841-A1 | TETRACYCLINE COMPOUNDS | TUBB, TUBA1A, TUBA1C | ELANE 2654/4885MAOB 1699/4885NR1H2 3345/4885 |
| US-20120208788-A1 | Tetracycline Compounds | TUBA1A, TUBA1C, TUBB1 | ELANE 2685/4885MAOB 2000/4885NR1H2 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.